You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Membrane repair as a therapeutic intervention for treating Becker Muscular Dystrophy

    SBC: MYOFINITY BIOSCIENCES INC            Topic: NIAMS

    PROJECT ABSTRACTThe goal of this combined Phase I/II SBIR project is to accomplish key milestones in commercializing a protein therapeutic for Becker muscular dystrophy (BMD) that will enhance the repair capacity of muscle cell sarcolemmal membranes compromised by mutations in the dystrophin gene that reduce the expression level or function of the dystrophin protein. Many mutations in the dystroph ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. A novel therapeutic for the treatment of biofilms in periprosthetic joint infections

    SBC: QENTOROS LLC            Topic: NIAID

    PROJECT SUMMARY Total joint arthroplasty (TJA) procedures are estimated to rise by over 300% by the year 2030. Periprosthetic joint infection (PJI) is the most significant complication following TJA with healthcare costs exceeding $1.6 billion annually. Treatment of PJI generally requires surgical intervention combined with a prolonged course of antibiotics costing $50,000 per patient. Despite thi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections

    SBC: Planet Biotechnology Incorporated            Topic: NIAID

    Burkholderia pseudomallei (Bp) is the causative agent of melioidosis, a major cause of morbidity and septic death in tropical/subtropical regions worldwide. It is particularly virulent in diabetic patients and is also considered a Tier 1 select agent due to its potential use as a bioweapon. These bacteria are naturally resistant to many antibiotics and there are currently no vaccines available. Th ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a first-in-class antiviral to address CMV drug resistance in immunocompromised patients

    SBC: VXBIOSCIENCES, INC.            Topic: NIAID

    ABSTRACT Human cytomegalovirus (CMV) infects a majority of the world’s population and is a leading cause of disease in transplant patients and newborns, accounting for more congenital birth defects than Down’s syndrome, spina bifida, or fetal alcohol syndrome. There is no approved vaccine and all current antiviral therapies for CMV prevention or treatment suffer from toxicity and a low barrier ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARYThe goal of this proposal is to optimize and clinically validate a new diagnostic test for eosinophilic chronic rhinosinusitis (eCRS) at the point-of-care, improving the efficiency, value, and accessibility of personalized medicine. eCRS affects up to 5 million Americans and is characterized by varying degrees of sinonasal and peripheral eosinophilia, linked to treatment responsiven ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)

    SBC: TRIANGLE THERAPEUTICS INC.            Topic: NIAID

    PROJECT SUMMARY Acute disseminated encephalomyelitis (ADEM) is an acute autoimmune disease that can present with fever and ataxia as well as loss of consciousness and coma. ADEM largely affects children, is driven by T and B lymphocytes aberrantly activated against a myelin antigen, and is strongly associated with a prior infection or immunization. There is no FDA-approved therapy for the treatmen ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Exploiting translation elongation for improved biologics manufacturing

    SBC: CODOMAX INC.            Topic: NCATS

    Abstract – Codomax has developed a codon engineering platform that enables bespoke, high-yield, cost- effective protein manufacturing by leveraging a newly discovered translational regulatory system in industrially relevant cell systems. Protein manufacturing has a current estimated market size of over $300 billion, distributed among the areas of antibodies and biologic therapeutics, biotechnolo ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. A Self-Guided Mobile Intervention for Adults with Binge Eating and Obesity

    SBC: OUI THERAPEUTICS INC            Topic: 104

    ABSTRACT Obesity and comorbid binge eating are serious health problems for more than 40% of adults across the US.7 Health complications due to obesity comprise more than 20% of the nation’s healthcare budget, and the healthcare costs of individuals with binge eating are $18,152 higher than in obese peers without binge eating.13 The prevalence of binge eating and the substantial burden of healthc ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Production of radiometal-based radiopharmaceuticals at a clinical scale via droplet-scale radiochemistry

    SBC: DropletPharm Inc.            Topic: NIBIB

    PROJECT SUMMARY Despite the enormous value of radiopharmaceuticals for imaging and therapy in clinical nuclear medicine, and for research and drug development, the production of these compounds remains very expensive because of the need for complex, capital-intensive equipment and infrastructure (i.e., hot cells, stack monitor, radiosynthesizer, and a suite of QC testing equipment) at each site. F ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Translational development of novel CRISPR approach to treat genomic duplications

    SBC: MYOFINITY BIOSCIENCES INC            Topic: NIAMS

    PROJECT ABSTRACT The goal of this Phase I STTR project is to accomplish key milestones in commercializing a novel SaCas9 nickase-based system (CRD-002) to treat dystrophinopathies in order to restore the production of healthy, endogenous full-length dystrophin protein otherwise compromised by duplication mutations. Duchenne muscular dystrophy (DMD) is characterized by progressive muscle loss and c ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government